$82.93
1.18%
Nasdaq, Oct 02, 04:01 pm EDT. Closed.
ISIN
US6047491013
Symbol
MIRM

Mirum Pharmaceuticals Inc Target price 2026 - Analyst rating & recommendation

Mirum Pharmaceuticals Inc Classifications & Recommendation

Buy
95%
Hold
5%

Mirum Pharmaceuticals Inc Price Target

Target Price $139.74
Price $82.93
Potential
Number of Estimates 16
16 Analysts have issued a price target Mirum Pharmaceuticals Inc 2027 . The average Mirum Pharmaceuticals Inc target price is $139.74. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 20 analysts: 19 Analysts recommend Mirum Pharmaceuticals Inc to buy, 1 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Mirum Pharmaceuticals Inc stock has an average upside potential 2027 of . Most analysts recommend the Mirum Pharmaceuticals Inc stock at Purchase.

Sales and Margin forecast 2026, 2027 to 2033

Create a premium account to unlock analyst estimates. Learn more

Select at least one metric to display the chart.


Quarter Annually
Dec '25 2026
Estimates
Revenue Million $ 521.31 711.12
54.74% 36.41%
EBITDA Margin 0.40% -129.65%
102.13% 32,132.15%
Net Margin -4.48% -141.11%
82.83% 3,049.06%

14 Analysts have issued a sales forecast Mirum Pharmaceuticals Inc 2026 . The average Mirum Pharmaceuticals Inc sales estimate is

$711m
unlock
. This is
15.05% higher
unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$741m 19.84%
unlock
, the lowest is
$672m 8.65%
unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2025 $521m 54.74%
2026
$711m 36.41%
unlock
2027
$832m 17.04%
unlock
2028
$1.1b 26.40%
unlock
2029
$1.4b 32.60%
unlock
2030
$1.8b 26.24%
unlock
2031
$2.1b 19.76%
unlock
2032
$2.4b 16.07%
unlock
2033
$2.5b 0.98%
unlock

5 Analysts have issued an Mirum Pharmaceuticals Inc EBITDA forecast 2026. The average Mirum Pharmaceuticals Inc EBITDA estimate is

$-922m
unlock
. This is
1,312.28% lower
unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$-885m 1,255.73%
unlock
, the lowest is
$-964m 1,376.76%
unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2025 $2.1m 103.30%
2026
$-922m 43,793.75%
unlock
2027
$-50.0m 94.57%
unlock
2028
$120m 340.32%
unlock

EBITDA Margin

2025 0.40% 102.13%
2026
-129.65% 32,132.15%
unlock
2027
-6.01% 95.36%
unlock
2028
11.43% 290.18%
unlock

16 Mirum Pharmaceuticals Inc Analysts have issued a net profit forecast 2026. The average Mirum Pharmaceuticals Inc net profit estimate is

$-1.0b
unlock
. This is
16.66% lower
unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$-929m 8.04%
unlock
, the lowest is
$-1.1b 28.04%
unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2025 $-23.4m 73.44%
2026
$-1.0b 4,195.72%
unlock
2027
$-63.5m 93.67%
unlock
2028
$118m 285.03%
unlock
2029
$373m 217.10%
unlock
2030
$645m 72.99%
unlock
2031
$877m 35.94%
unlock
2032
$1.0b 15.74%
unlock
2033
$1.1b 11.13%
unlock

Net Margin

2025 -4.48% 82.83%
2026
-141.11% 3,049.06%
unlock
2027
-7.63% 94.59%
unlock
2028
11.18% 246.53%
unlock
2029
26.73% 139.09%
unlock
2030
36.62% 37.00%
unlock
2031
41.57% 13.52%
unlock
2032
41.45% 0.29%
unlock
2033
45.62% 10.06%
unlock

Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033

Create a premium account to unlock analyst estimates. Learn more

Select at least one metric to display the chart.


Quarter Annually
Dec '25 2026
Estimates
Earnings Per Share $ -0.47 -15.50
74.59% 3,197.87%
P/E negative
EV/Sales 8.01

16 Analysts have issued a Mirum Pharmaceuticals Inc forecast for earnings per share. The average Mirum Pharmaceuticals Inc EPS is

$-15.50
unlock
. This is
14.22% lower
unlock
than earnings per share in the financial year 2025. The highest EPS forecast is
$-14.35 5.75%
unlock
, the lowest is
$-17.01 25.35%
unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2025 $-0.47 74.59%
2026
$-15.50 3,197.87%
unlock
2027
$-0.98 93.68%
unlock
2028
$1.82 285.71%
unlock
2029
$5.76 216.48%
unlock
2030
$9.96 72.92%
unlock
2031
$13.54 35.94%
unlock
2032
$15.67 15.73%
unlock
2033
$17.42 11.17%
unlock

P/E ratio

Current -6.11 90.17%
2026
-5.35 12.46%
unlock
2027
-84.51 1,479.63%
unlock
2028
45.67 154.04%
unlock
2029
14.40 68.47%
unlock
2030
8.33 42.15%
unlock
2031
6.12 26.53%
unlock
2032
5.29 13.56%
unlock
2033
4.76 10.02%
unlock

Based on analysts' sales estimates for 2026, the Mirum Pharmaceuticals Inc stock is valued at an EV/Sales of

and an P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 9.22 8.09%
2026
8.01 13.11%
unlock
2027
6.84 14.56%
unlock
2028
5.42 20.89%
unlock
2029
4.08 24.59%
unlock
2030
3.23 20.78%
unlock
2031
2.70 16.50%
unlock
2032
2.33 13.85%
unlock
2033
2.30 0.97%
unlock

P/S ratio

Current 8.71 2.29%
2026
7.57 13.08%
unlock
2027
6.47 14.56%
unlock
2028
5.12 20.89%
unlock
2029
3.86 24.59%
unlock
2030
3.06 20.78%
unlock
2031
2.55 16.50%
unlock
2032
2.20 13.85%
unlock
2033
2.18 0.97%
unlock

Current Mirum Pharmaceuticals Inc Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
Citigroup
Locked
➜
Locked
Locked Sep 29 2026
Baird
Locked
➜
Locked
Locked Sep 29 2026
HC Wainwright & Co.
Locked
➜
Locked
Locked Sep 28 2026
Citizens
Locked
➜
Locked
Locked Aug 27 2026
HC Wainwright & Co.
Locked
➜
Locked
Locked Aug 06 2026
Citizens
Locked
➜
Locked
Locked Aug 06 2026
RBC Capital
Locked
➜
Locked
Locked Aug 06 2026
Analyst Rating Date
Locked
Citigroup:
Locked
➜
Locked
Sep 29 2026
Locked
Baird:
Locked
➜
Locked
Sep 29 2026
Locked
HC Wainwright & Co.:
Locked
➜
Locked
Sep 28 2026
Locked
Citizens:
Locked
➜
Locked
Aug 27 2026
Locked
HC Wainwright & Co.:
Locked
➜
Locked
Aug 06 2026
Locked
Citizens:
Locked
➜
Locked
Aug 06 2026
Locked
RBC Capital:
Locked
➜
Locked
Aug 06 2026

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today